Drug Profile
ALN PCS
Alternative Names: ALN-PCS; ALN-PCS01; ALN-PCS02Latest Information Update: 17 Jan 2020
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Class Antihyperlipidaemics; Small interfering RNA
- Mechanism of Action PCSK9 protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 06 Jan 2020 The Medicines Company has been acquired by Novartis
- 08 Feb 2017 The Supreme Court of British Columbia grants a pre-trial injunction filed against Acuitas Therapeutics by Arbutus Biopharma for Arbutus's lipid nanoparticle (LNP) technology
- 05 Nov 2014 Alnylam receives patent allowance for RNA interference technology in USA